



**Pending Claims of 09/934,289
in Response to the Restriction Requirement
Dated September 3, 2002**

23. (New) An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:17, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, or a complement thereof.

24. (New) The polypeptide of claim 23, encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 98% identical to the nucleotide sequence of SEQ ID NO:17, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, or a complement thereof.

25. (New) The polypeptide of claim 23, encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:17 or the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173..

26. (New) An isolated polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:18.

27. (New) The polypeptide of claim 26, further comprising an amino acid sequence which is at least 98% identical to the amino acid sequence of SEQ ID NO:18.

28. (New) A naturally occurring allelic variant of a polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:18.

29. (New) The naturally occurring allelic variant of claim 28, wherein the polypeptide further comprises an amino acid sequence which is at least 98% identical to the amino acid sequence of SEQ ID NO:18

30. (New) An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO:17, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, or a complement thereof, wherein said polypeptide is soluble, lacks a transmembrane domain and a cytoplasmic domain, and exhibits a human TANGO-69-receptor activity.

31. (New) The polypeptide of claim 30, encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 92.5% identical to the nucleotide sequence of SEQ ID NO:17, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, or a complement thereof.

32. (New) An isolated soluble polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO:18, wherein said protein lacks a transmembrane domain and a cytoplasmic domain, and exhibits a human TANGO-69-receptor activity.

33. (New) The polypeptide of claim 32, further comprising an amino acid sequence which is at least 85% identical to the amino acid sequence of SEQ ID NO:18.

34. (New) The polypeptide of claim 32, further comprising an amino acid sequence which is at least 90% identical to the amino acid sequence of SEQ ID NO:18.

35. (New) The polypeptide of claim 23, further comprising heterologous amino acid sequences.

36. (New) The polypeptide of claim 26, further comprising heterologous amino acid sequences.

37. (New) The polypeptide of claim 30, further comprising heterologous amino acid sequences.

38. (New) The polypeptide of claim 32, further comprising heterologous amino acid sequences.